Welcome to our dedicated page for CytoMed Therapeutics news (Ticker: GDTC), a resource for investors and traders seeking the latest updates and insights on CytoMed Therapeutics stock.
CytoMed Therapeutics Limited (NASDAQ: GDTC) is a Singapore-based clinical stage biopharmaceutical company developing donor-derived, cell-based allogeneic immunotherapies for cancers. This news page aggregates company announcements, clinical updates and regulatory disclosures so readers can follow how CytoMed’s gamma delta T cell and iPSC-derived platforms progress from research into clinical application.
According to its public communications, CytoMed is advancing a Phase I CAR gamma delta T cell trial in Singapore (the ANGELICA Trial), supporting a Phase II Investigator-Initiated Trial in India, and preparing a first-in-human trial in Malaysia for unmodified allogeneic γδ T cells in collaboration with Universiti Malaya. News items frequently cover milestones such as completion of dose levels in the ANGELICA Trial, memoranda of understanding with hospital partners, and publications of collaborative research with institutions like The University of Texas MD Anderson Cancer Center on donor-derived Vγ9Vδ2 T cells for acute myeloid leukemia.
Investors and observers can also find updates on CytoMed’s corporate developments, including the build-out of its cord blood-derived platform under subsidiary LongevityBank, the acquisition of a licensed cord blood bank in Malaysia, and non-dilutive investment into LongevityBank. Additional announcements may describe asset acquisitions related to T cell technologies, at-the-market equity programs, and changes in significant shareholdings.
For those tracking GDTC, this news feed provides a centralized view of CytoMed’s progress in oncology-focused cell therapies, its expansion into cord blood-derived and regenerative applications, and its evolving strategy in Southeast Asia, India and China. Regularly reviewing these updates can help readers understand how the company’s clinical, scientific and corporate activities develop over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.